ショアンシェン・デコクションの発表: 慢性便秘に対する新しいアプローチ
Xing-Lin Zeng1,2, Lian-Jun Zhu1,3, Yu Zhang3
1Clinical Medicine College, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
World journal of gastroenterology
|September 4, 2025
まとめ
Xuanshen decoction (XSD) は,腸内細胞の酸化ストレスとアポトーシスを減少させることで,遅い経路便秘 (STC) を効果的に治療します. この伝統的な中国の薬は,治療効果のためにフォスフォノシチド3キナーゼ/タンパク質キナーゼB/核因子エリソイド2に関連する因子2経路を刺激します.
科学分野:
- 胃腸内科
- 薬理学について
- 中国 伝統 医学
背景:
- 慢性便秘 (STC) は,治療の選択肢が限られている機能的な胃腸疾患です.
- Xuanshen decoction (XSD) は,STCに使用される伝統的な中国医学 (TCM) の配方ですが,その正確な作用メカニズムは完全に理解されていません.
研究 の 目的:
- STCの治療におけるXSDの治療メカニズムを解明する.
- STCラットモデルにおける酸化ストレス,アポトーシス,および関連するシグナル伝達経路に対するXSDの影響を調査する.
主な方法:
- ラットにおけるロペラミド誘発性STCを用いたネットワーク薬理学,分子ドッキング,およびin vivoの研究を組み合わせた.
- 糞便のパラメータと腸内経路でXSDの有効性を評価した.
- 大腸内粘膜の組織病変,粘素の産生,そして主要なタンパク質の発現レベルを分析した.
主要な成果:
- 糞便と水分を増加させるなど,XSDはラットにおけるSTC症状を大幅に改善しました.
- XSD治療は,幹細胞因子,Cキット,カタラーゼ,スーパーオキシドディスミュータゼ,核因子エリソイド2関連因子2 (Nrf2),B細胞リンパ腫2 (Bcl-2) などの保護因子を上限化する.
- XSDは,Bcl-2-関連Xタンパク質 (Bax) / Bcl-2比率などのプロアポトシスマーカーを低下させ,酸化ストレスとアポトシスの減少を示した.
結論:
- XSDは,オキシダティブ・ストレスの誘発によるCajalのインタースティシャル細胞におけるアポトーシスを軽減することによって,STCを効果的に治療します.
- 治療メカニズムは,フォスフォノシチド3キナーゼ (PI3K) / タンパク質キナーゼB (Akt) / 核因子エリソイド2関連因子2 (Nrf2) 信号経路の活性化である.
- XSDは多標的効果により,STCに対する有望な治療戦略を提供します.
関連する概念動画
01:21Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
01:17Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
303
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
303
01:20Drugs Affecting GI Tract Motility: Other Laxatives
443
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
443
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
316
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
316